Mylan Misconduct Fine In Actos Suit Could Alter Future Generic Challenges
Executive Summary
Generic drug manufacturers may be more cautious in challenging the validity of a brand name company's patent after an appeals court affirmed that Takeda was entitled to $16.8 million in attorneys fees in litigation over its diabetes drug Actos